ClinicalTrials.gg
Not yet recruitingNCT07398027CRONOS-CHUpdated Feb 9, 2026

Post-Market Study of Transbronchial Cryo-assisted RFA During Robotic Bronchoscopy With Subsequent Surgical Resection

An interventional study of HybridTherm® System in Lung Cancer, sponsored by Carolin Steinack. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Carolin Steinack · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Lung Neoplasms with a site in Switzerland — 26 open to participants now, 32 under way, 11 of them phase 3. Lung Neoplasms · Switzerland.

Planned enrollment
69th of 77
20 · median 136
Started
2026
with 4 others
No phase
13 of 98
6 open now
Primary completion
2027-03
later than 7 of 31 live
Registered
95th of 98
by date

Among the 98 studies in Lung Neoplasms with a site in Switzerland, this one is the 69th largest by planned enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 with no phase, reaches primary completion later than 7 of the 31 other live ones, and was the 95th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

26 of the 98 studies in Lung Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lung Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of this study is to confirm the procedural feasibility and device usability of the HybridTherm® system during bronchoscopic cryo-assisted radiofrequency ablation (RFA) performed prior to scheduled surgical resection in patients with lung cancer. The bronchoscopy session includes tumor ablation and, when clinically indicated, mediastinal lymph node staging by EBUS-TBNA.

Read the detailed description

This is a prospective, single-arm, post-market clinical investigation conducted in Switzerland to collect clinical data on the use, safety, and performance of the CE-marked HybridTherm® system during routine bronchoscopic tumor management procedures. The investigation is classified as a ClinO-MD Category A1 medical device study, as the HybridTherm® system is CE-marked and used strictly within its intended purpose under normal conditions of clinical use.

The investigation is investigator-initiated and single-center, conducted at the University Hospital Zurich. The Sponsor-Investigator is responsible for the initiation, conduct, management, safety oversight, and data handling of the study in accordance with the Swiss Human Research Act (HRA), the Ordinance on Clinical Trials with Medical Devices (ClinO-MD), ISO 14155, and applicable ethical requirements. Ethics Committee approval is required prior to study initiation, and the investigation will begin only after a positive written decision from the competent cantonal ethics committee has been obtained.

The HybridTherm® system is a bipolar cryo-cooled radiofrequency ablation device intended for incision, coagulation, and ablation of tissue during flexible endoscopic procedures in the tracheobronchial system. The system provides internally cooled radiofrequency energy to delay tissue desiccation and impedance rise, thereby enabling controlled energy delivery during ablation. In this investigation, the device is used during clinically indicated bronchoscopic procedures without deviation from its approved indication or standard clinical workflow.

All enrolled participants undergo diagnostic bronchoscopy as part of routine clinical care, including mediastinal lymph node staging when clinically indicated. Transbronchial cryo-assisted radiofrequency ablation is performed during the same bronchoscopy session under general anesthesia. Surgical resection of the targeted lung lesion follows according to the established oncologic treatment plan and is not altered by study participation. No randomization, blinding, or comparator intervention is included.

Data collected in this investigation are derived exclusively from standard-of-care procedures, routine imaging, device readouts, and histopathological assessment of resected specimens. No additional diagnostic tests, therapeutic interventions, or protocol-mandated procedures beyond routine clinical practice are introduced. All analyses are descriptive in nature and are intended to support post-market evaluation of procedural feasibility, safety, and device usability.

The investigation is designed to generate clinical experience and safety data that may inform future clinical research and support the continued evaluation of bronchoscopic cryo-assisted radiofrequency ablation using the HybridTherm® system within standard treatment pathways.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who require diagnostic bronchoscopy for suspicious lung lesions with mediastinal lymph node status confirmed as NO by one of the following: Prior PET-CT showing no FDG-avid mediastinal lymph nodes, OR intraoperative EBUS-TBNA with ROSE confirming negative lymph nodes (performed when clinically indicated per section 6.1).
  • Solitary pulmonary lesions ≤ 2.5cm with or cytologically confirmed primary lung cancer.
  • Suitable candidate for surgical resection of the tumor targeted for ablation
  • Interdisciplinary tumor board consent
  • Ability to read, understand, and sign patient Form (ICF)
  • Age ≥ 18-years-old
  • ≥ 20 mm of free space between the calculated intended ablation zone and the lung parenchyma or any critical structures (pleura, vessels and main bronchi).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (breast feeding) females
  • Central tumors abutting vital structures (main bronchus, pulmonary artery, esophagus, trachea)
  • Thoracic electronic implants (e.g., pacemakers, ICDs)
  • Uncorrectable coagulopathy or count ≤ 50,000/mm³
  • Patients receiving anticoagulant therapy or with pulmonary hypertension that, in the opinion of the Investigator, poses an unacceptable safety risk for bronchoscopy and ablation.
  • Severe, uncontrolled comorbidities
  • Active systemic infection
  • Prior radiation therapy (SBRT) in the intended ablation zone
  • Recent therapy within the last 30 days that the investigator deems could interfere with proceeding in the clinical investigation
  • Tumors associated with atelectasis, obstructive pneumonitis, pleural effusion, or fibrosis
  • Investigators determine that study participation poses safety risk
  • Any comorbidities judged by the principal Investigator to be for bronchoscopy
  • Subject was judged unsuitable for study participation by the Investigator for any other reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    HybridTherm Cryo-Assisted RFA & surgical resection

    Participants undergo transbronchial cryo-assisted radiofrequency ablation (RFA) using the CE-marked HybridTherm® system during routine diagnostic bronchoscopy. When clinically indicated, mediastinal lymph node staging by performed. Surgical resection of the treated lung lesion follows according to the standard clinical treatment plan.

    Device: HybridTherm® System

Interventions

  • DeviceHybridTherm® System

    Transbronchial cryo-assisted radiofrequency ablation (RFA) performed using the CE-marked HybridTherm® system during routine diagnostic bronchoscopy, within the intended use of the device.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Successful Completion of Bronchoscopic Cryo-assisted RFA Using the HybridTherm® System

    Successful device use, defined as the completion of ablation with the HybridTherm® system with investigator confirmation that the ablation zone achieved sufficient coverage based on intra-procedural imaging

    Time frame: Day 0 (Diagnostic Bronchoscopy and RFA Procedure)

  2. Number of Participants with Bleeding-Related Serious Adverse Events Associated with the Investigational Device and/or RFA Procedure

    Number of Serious Adverse Events (SAEs) associated with bleeding related to the investigational device and/or radiofrequency ablation (RFA) procedure.

    Time frame: From Day 0 (Diagnostic Bronchoscopy and RFA Procedure) through End of Study (6-7 weeks post-procedure)

  3. Severity of Bleeding-Related Adverse Events as Assessed by the Nashville Bleeding Scale

    Safety assessments for bleeding Adverse Events (AEs) related to the investigational device and/or radiofrequency ablation (RFA) procedure, graded using the Nashville bleeding scale.

    Time frame: From Day 0 (Diagnostic Bronchoscopy and RFA Procedure) through End of Study (6-7 weeks post-procedure)

Secondary outcomes

  1. Total Number of Serious Adverse Events Related to the Investigational Device and/or RFA Procedure

    Total number of Serious Adverse Events (SAEs) related to the investigational device and/or radiofrequency ablation (RFA) procedure.

    Time frame: From Day 0 (Diagnostic Bronchoscopy and RFA Procedure) through End of Study (6-7 weeks post-procedure)

  2. Total Number of Adverse Events Related to the Investigational Device and/or RFA Procedure

    Total number of Adverse Events (AEs) related to the investigational device and/or radiofrequency ablation (RFA) procedure.

    Time frame: From Day 0 (Diagnostic Bronchoscopy and RFA Procedure) through End of Study (6-7 weeks post-procedure)

  3. Macroscopic and Microscopic Evidence of Ablation in the Resected Specimen

    Macroscopic and microscopic evidence of ablation in the resected specimen, assessed using standard histopathological methods (hematoxylin and eosin staining).

    Time frame: At Surgical Resection (7-14 Days Post-Procedure)

  4. Percentage of Tumor Necrosis Within the Ablation Zone

    Visual estimation of histopathologic ablation completeness, defined as the percentage of tumor necrosis within the ablation zone, as determined by routine pathology reporting.

    Time frame: At Surgical Resection (7-14 Days Post-Procedure)

  5. Histopathologic Complete Response (Absence of Viable Tumor Cells) Within the Ablation Zone

    Evaluation of macroscopic and microscopic necrosis within the ablation zone, defined as the absence of viable tumor cells within the ablated area (histopathologic complete response, hpCR), if reported as part of routine histological assessment. If applicable, the extent of necrosis into surrounding parenchyma or margin tissue will be noted.

    Time frame: At Surgical Resection (7-14 Days Post-Procedure)

  6. Composite Descriptive Intra-Procedural Metrics During Bronchoscopic Cryo-assisted RFA

    Descriptive intra-procedural metrics collected during the bronchoscopic cryo-assisted radiofrequency ablation (RFA) procedure, including total ablation time (minutes), number of cryoRFA activations (energy applications), electrical parameters of energy delivered (if available), number of probe repositionings within the lesion, and estimated ablation zone size (millimeters) derived from intraoperative imaging when obtained as part of routine clinical practice. These measures are collected for descriptive characterization of procedural performance and are not intended for separate outcome analysis.

    Time frame: Day 0 (Diagnostic Bronchoscopy and RFA Procedure)

07

Study locations

1 site
08

References and documents

Publications

  • Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S. Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World J Gastrointest Endosc. 2017 Feb 16;9(2):41-54. doi: 10.4253/wjge.v9.i2.41. PubMed 28250896 ↗
  • Dabizzi E, Testoni SG, Barbera M et al. 484 EUS-GUIDED CRYOTHERM ABLATION OF STAGE III PANCREATIC ADENOCARCINOMA: A PRELIMINARY RADIOLOGICAL PERSPECTIVE. Gastrointest Endosc 2018; 87: AB84
  • Testoni SGG, Petrone MC, Reni M, Di Serio C, Rancoita PM, Rossi G, Balzano G, Linzenbold W, Enderle M, Della-Torre E, De Cobelli F, Falconi M, Capurso G, Arcidiacono PG. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control study. Endosc Ultrasound. 2022 Sep-Oct;11(5):383-392. doi: 10.4103/EUS-D-21-00200. PubMed 36255026 ↗
  • Testoni SGG, Petrone MC, Reni M, Rossi G, Barbera M, Nicoletti V, Gusmini S, Balzano G, Linzenbold W, Enderle M, Della-Torre E, De Cobelli F, Doglioni C, Falconi M, Capurso G, Arcidiacono PG. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial. Cancers (Basel). 2021 Sep 8;13(18):4512. doi: 10.3390/cancers13184512. PubMed 34572743 ↗
  • Arcidiacono PG, Carrara S, Reni M, Petrone MC, Cappio S, Balzano G, Boemo C, Cereda S, Nicoletti R, Enderle MD, Neugebauer A, von Renteln D, Eickhoff A, Testoni PA. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc. 2012 Dec;76(6):1142-51. doi: 10.1016/j.gie.2012.08.006. Epub 2012 Sep 26. PubMed 23021160 ↗
  • Ahmed M, Liu Z, Afzal KS, Weeks D, Lobo SM, Kruskal JB, Lenkinski RE, Goldberg SN. Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model. Radiology. 2004 Mar;230(3):761-7. doi: 10.1148/radiol.2303021801. PubMed 14990840 ↗
  • International Conference on Harmonization (ICH) Guideline for Good Clinical Practice E6(R2), (www.ich.org).
  • Strahlenschutzverordnung (StSV) vom 26. April 2017 / Ordonnance sur la radioprotection (ORaP) du 26 avril 2017 / Ordinanza sulla radioprotezione (ORaP) del 26 aprile 2017
  • WHO, International Clinical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/en/)
  • EN ISO 14971: Application of risk management to medical devices (www.iso.org)
  • EN ISO 10993: Biological evaluation of medical devices (www.iso.org)
  • EN ISO 14155: Clinical investigation of medical devices for human subjects - Good clinical practice (www.iso.org)
  • MDCG 2020-10/1 Safety reporting in clinical investigations of medical devices under the Regulation (EU) 2017/745 (https://ec.europa.eu/health/sites/health/files/md_sector/docs/md_mdcg_2020-10-1_guidance_safety_reporting_en.pdf)
  • MDCG 2024-3 Guidance on content of the Clinical Investigation Plan for clinical investigations of medical devices
  • Medical Device Regulation (EU) 2017/745 of 5 April 2017 (MDR)
  • Medizinprodukteverordnung (MepV) vom 17. Oktober 2001 / Ordonnance sur les dispositifs médicaux (ODim) du 17 octobre 2001 / Ordinanza relativa ai dispositivi medici (ODmed) del 17 ottobre 2001
  • Verordnung über klinische Versuche mit Ausnahme klinischer Versuche mit Medizinprodukten (Verordnung über klinische Versuche, KlinV) vom 20. September 2013 / Ordonnance sur les essais cliniques hors essais cliniques de dispositifs médicaux (Ordonnance sur les essais cliniques, OClin) du 20 septembre 2013. Ordinanza sulle sperimentazioni cliniche ad eccezione delle sperimentazioni cliniche con dispositivi medici (Ordinanza sulle sperimentazioni cliniche, OSRUm) del 20 settembre 2013
  • Verordnung über klinische Versuche mit Medizinprodukten (KlinV-Mep) vom 1. Juli 2020 / Ordonnance sur les essais cliniques de dispositifs médicaux (OClin-Dim) du 1er juillet 2020 /. Ordinanza sulle sperimentazioni cliniche con dispositivi medici (OSRUm-Dmed) del 1 luglio 2020
  • Humanforschungsgesetz, HFG Bundesgesetz über die Forschung am Menschen (Bundesgesetz über die Forschung am Menschen, HFG) vom 30. September 2011/ Loi fédérale relative à la recherche sur l'être humain (loi relative à la recherche sur l'être humain, LRH) du 30 septembre 2011 / Legge federale concernente la ricerca sull'essere umano (Legge sulla ricerca umana, LRUm) del 30 settembre 2011
  • Steinfort DP, Herth FJF. Bronchoscopic treatments for early-stage peripheral lung cancer: Are we ready for prime time? Respirology. 2020 Sep;25(9):944-952. doi: 10.1111/resp.13903. Epub 2020 Jul 8. PubMed 32643221 ↗
  • Koizumi T, Tsushima K, Tanabe T, Agatsuma T, Yokoyama T, Ito M, Kanda S, Kobayashi T, Yasuo M. Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer. Respiration. 2015;90(1):47-55. doi: 10.1159/000430825. Epub 2015 May 30. PubMed 26044954 ↗
  • Tanabe T, Koizumi T, Tsushima K, Ito M, Kanda S, Kobayashi T, Yasuo M, Yamazaki Y, Kubo K, Honda T, Kondo R, Yoshida K. Comparative study of three different catheters for CT imaging-bronchoscopy-guided radiofrequency ablation as a potential and novel interventional therapy for lung cancer. Chest. 2010 Apr;137(4):890-7. doi: 10.1378/chest.09-1065. Epub 2009 Oct 26. PubMed 19858232 ↗
  • Ishiwata T, Motooka Y, Ujiie H, Inage T, Gregor A, Aragaki M, Chen Z, Kinoshita T, Donahoe L, Yeung J, Cypel M, de Perrot M, Pierre A, Darling G, Waddell T, Keshavjee S, Pal P, Yasufuku K. Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial. J Thorac Cardiovasc Surg. 2022 Oct;164(4):1188-1197.e2. doi: 10.1016/j.jtcvs.2021.12.059. Epub 2022 Mar 26. PubMed 35459539 ↗
  • Koizumi T, Kobayashi T, Tanabe T, Tsushima K, Yasuo M. Clinical experience of bronchoscopy-guided radiofrequency ablation for peripheral-type lung cancer. Case Rep Oncol Med. 2013;2013:515160. doi: 10.1155/2013/515160. Epub 2013 Sep 11. PubMed 24106625 ↗
  • Steinfort DP, Antippa P, Rangamuwa K, Irving LB, Christie M, Chan E, Marinelli B, Wang J, Yoneda KY, Raina S, Herth FJ. Safety and Feasibility of a Novel Externally Cooled Bronchoscopic Radiofrequency Ablation Catheter for Ablation of Peripheral Lung Tumours: A First-In-Human Dose Escalation Study. Respiration. 2023;102(3):211-219. doi: 10.1159/000529167. Epub 2023 Jan 31. PubMed 36720208 ↗
  • Xie F, Zheng X, Xiao B, Han B, Herth FJF, Sun J. Navigation Bronchoscopy-Guided Radiofrequency Ablation for Nonsurgical Peripheral Pulmonary Tumors. Respiration. 2017;94(3):293-298. doi: 10.1159/000477764. Epub 2017 Jul 6. PubMed 28683443 ↗
  • Steinke K, King J, Glenn D, Morris DL. Pulmonary hemorrhage during percutaneous radiofrequency ablation: a more frequent complication than assumed? Interact Cardiovasc Thorac Surg. 2003 Dec;2(4):462-5. doi: 10.1016/S1569-9293(03)00123-3. PubMed 17670096 ↗
  • Vaughn C, Mychaskiw G 2nd, Sewell P. Massive hemorrhage during radiofrequency ablation of a pulmonary neoplasm. Anesth Analg. 2002 May;94(5):1149-51; table of contents. doi: 10.1097/00000539-200205000-00016. PubMed 11973177 ↗
  • Vogl TJ, Eckert R, Naguib NN, Beeres M, Gruber-Rouh T, Nour-Eldin NA. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation. AJR Am J Roentgenol. 2016 Dec;207(6):1340-1349. doi: 10.2214/AJR.15.14401. Epub 2016 Sep 28. PubMed 27680945 ↗
  • Aufranc V, Farouil G, Abdel-Rehim M, Smadja P, Tardieu M, Aptel S, Guibal A. Percutaneous thermal ablation of primary and secondary lung tumors: Comparison between microwave and radiofrequency ablation. Diagn Interv Imaging. 2019 Dec;100(12):781-791. doi: 10.1016/j.diii.2019.07.008. Epub 2019 Aug 8. PubMed 31402333 ↗
  • Grasso RF, Bernetti C, Pacella G, Altomare C, Castiello G, Andresciani F, Sarli M, Zobel BB, Faiella E. A comparative analysis of thermal ablation techniques in the treatment of primary and secondary lung tumors: a single-center experience. Radiol Med. 2022 Jul;127(7):714-724. doi: 10.1007/s11547-022-01508-2. Epub 2022 Jun 14. PubMed 35701683 ↗
  • Shi F, Li G, Zhou Z, Xu R, Li W, Zhuang W, Chen Z, Chen X. Microwave ablation versus radiofrequency ablation for the treatment of pulmonary tumors. Oncotarget. 2017 Nov 7;8(65):109791-109798. doi: 10.18632/oncotarget.22308. eCollection 2017 Dec 12. PubMed 29312649 ↗
  • Chi J, Ding M, Shi Y, Wang T, Cui D, Tang X, Li P, Zhai B. Comparison study of computed tomography-guided radiofrequency and microwave ablation for pulmonary tumors: A retrospective, case-controlled observational study. Thorac Cancer. 2018 Oct;9(10):1241-1248. doi: 10.1111/1759-7714.12822. Epub 2018 Aug 1. PubMed 30070054 ↗
  • Iezzi R, Larici AR, Posa A, Carchesio F, Congedo MT, Tagliaferri L, Cassano A, D'argento E, Mantini G, Rodolfino E, Margaritora S, Bria E, Tortora G, Valentini V, Manfredi R. Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors. Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6554-6561. doi: 10.26355/eurrev_201908_18541. PubMed 31378896 ↗
  • Mu L, Pan T, Lyu N, Sun L, Li S, Xie Q, Deng H, Wu P, Liu H, Zhao M. CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. Lung Cancer. 2018 Aug;122:25-31. doi: 10.1016/j.lungcan.2018.05.004. Epub 2018 May 12. PubMed 30032841 ↗
  • Yang Q, Luo LC, Li FM, Yi Q, Luo W. Survival outcomes of radiofrequency ablation compared with surgery in patients with early-stage primary non-small-cell lung cancer: A meta-analysis. Respir Investig. 2022 May;60(3):337-344. doi: 10.1016/j.resinv.2022.01.002. Epub 2022 Feb 13. PubMed 35172951 ↗
  • Rempp H, Voigtlander M, Clasen S, Kempf S, Neugebauer A, Schraml C, Schmidt D, Claussen CD, Enderle MD, Goldberg SN, Pereira PL. Increased ablation zones using a cryo-based internally cooled bipolar RF applicator in ex vivo bovine liver. Invest Radiol. 2009 Dec;44(12):763-8. doi: 10.1097/RLI.0b013e3181b66d11. PubMed 19838120 ↗
  • de Baere T, Tselikas L, Catena V, Buy X, Deschamps F, Palussiere J. Percutaneous thermal ablation of primary lung cancer. Diagn Interv Imaging. 2016 Oct;97(10):1019-1024. doi: 10.1016/j.diii.2016.08.016. Epub 2016 Sep 28. PubMed 27692673 ↗
  • Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008 Jul;9(7):621-8. doi: 10.1016/S1470-2045(08)70155-4. Epub 2008 Jun 17. PubMed 18565793 ↗
  • Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000 Jan;174(1):57-9. doi: 10.2214/ajr.174.1.1740057. No abstract available. PubMed 10628454 ↗
  • Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, Franks K, Gleeson F, Graham R, Malhotra P, Prokop M, Rodger K, Subesinghe M, Waller D, Woolhouse I; British Thoracic Society Pulmonary Nodule Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015 Aug;70 Suppl 2:ii1-ii54. doi: 10.1136/thoraxjnl-2015-207168. No abstract available. PubMed 26082159 ↗
  • Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222. No abstract available. PubMed 28881918 ↗
  • Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lubbe AS, Reinhold T, Spath-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeboller H, Bocking A, Bohle RM, Bruske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gutz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heussel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hubner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Muller KM, Muller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rube C, Schmittel A, Schonfeld N, Schutte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H; Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin und die Deutsche Krebsgesellschaft. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie. 2010 Mar;64 Suppl 2:e1-164. doi: 10.1055/s-0029-1243837. Epub 2010 Mar 9. No abstract available. German. PubMed 20217630 ↗
  • Al-Alem I, Pillai K, Akhter J, Chua TC, Morris DL. Heat sink phenomenon of bipolar and monopolar radiofrequency ablation observed using polypropylene tubes for vessel simulation. Surg Innov. 2014 Jun;21(3):269-76. doi: 10.1177/1553350613505713. Epub 2013 Oct 16. PubMed 24132470 ↗
  • Liu Z, Ahmed M, Weinstein Y, Yi M, Mahajan RL, Goldberg SN. Characterization of the RF ablation-induced 'oven effect': the importance of background tissue thermal conductivity on tissue heating. Int J Hyperthermia. 2006 Jun;22(4):327-42. doi: 10.1080/02656730600609122. PubMed 16754353 ↗
  • Palussiere J, Catena V, Buy X. Percutaneous thermal ablation of lung tumors - Radiofrequency, microwave and cryotherapy: Where are we going? Diagn Interv Imaging. 2017 Sep;98(9):619-625. doi: 10.1016/j.diii.2017.07.003. Epub 2017 Aug 24. PubMed 28844613 ↗
  • Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT Jr, Brace CL. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation--what should you use and why? Radiographics. 2014 Sep-Oct;34(5):1344-62. doi: 10.1148/rg.345140054. PubMed 25208284 ↗
  • Dupuy DE, Zuromski J, Pennathur A. Ablation for treating small pulmonary nodules: radiologic and surgical approach and perspectives. Curr Chall Thorac Surg 2022; 4: 40
  • Long G, Bakos G, Shires PK, Gritter L, Crissman JW, Harris JL, Clymer JW. Histological and finite element analysis of cell death due to irreversible electroporation. Technol Cancer Res Treat. 2014 Dec;13(6):561-9. doi: 10.7785/tcrtexpress.2013.600253. Epub 2013 Aug 31. PubMed 24000980 ↗
  • Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, David E, Detterbeck F, Fruh M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB 2nd. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022 Apr 20;40(12):1356-1384. doi: 10.1200/JCO.21.02528. Epub 2021 Dec 22. PubMed 34936470 ↗
  • Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e278S-e313S. doi: 10.1378/chest.12-2359. PubMed 23649443 ↗
  • Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1. No abstract available. PubMed 33532112 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • Declaration of Helsinki, Version October 2013 (http://www.wma.net)

Individual participant data

Plan to share: No — Individual participant data will not be shared due to local data protection requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 12 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Feb 9, 2026
StartEst.
Mar 2026
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07398027
Lead sponsor
Carolin Steinack
Collaborators
Erbe Elektromedizin GmbH
Responsible party
Carolin Steinack (Head of Interventional Pulmonology, Sponsor, Principal Investigator, University of Zurich) — Sponsor-investigator
First posted
Feb 9, 2026
Start date
Mar 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 9, 2026

Study contacts

Dr. Carolin Steinack, Head of Interventional Pulmonology
Contact
carolin.steinack@usz.ch
+41 76 771 37 79
Thomas Gaisl, MD
Contact
thomas.gaisl@usz.ch
+41 76 771 37 79

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion